Table 1.
Icotinib in second-line therapy and above
| Study | Number of Cases | Proportion of adenocarcinoma | OR | DCR | PFS, months | OS, months | Rash | Diarrhea | Dysfunction of liver |
|---|---|---|---|---|---|---|---|---|---|
| Li et al15 | 30 | 90% | 46.7% | 73.3% | – | – | 43.3% | 23.3% | 10% |
| Chen et al16 | 67 | 91% | 38.8% | 62.7% | – | – | 26.8% | 13.4% | 10.4% |
| Nong et al17 | 60 | 90% | 45% | 80% | 6.7 | – | 38.3% | 14.2% | 1.7% |
| Zhang et al18 | 31 | 77.4% | 38.7% | 87.1% | 6.5 | – | 22.6% | 12.9% | 3.2% |
| Su et al19 | 38 | 94.7% | 76.3% | 100% | 10 | – | 63.2% | 28.9% | 10.5% |
| Shao et al20 | 149 | 69.1% | 22.1% | 71.8% | 5.03 | 12.3 | 40.9% | 18.1% | 7.4% |
| Zhang et al21 | 40 | 85% | 25% | 70% | 5.3 | 15.1 | 25% | 7.5% | – |
| Zhang et al22 | 51 | 100% | 23.5% | 76.5% | 5.1 | 12.5 | 29.4% | 17.6% | – |
| He et al23 | 31 | 0%* | 6.5% | 38.7% | 2.1 | 21.8 | 38.7% | 16.1% | 6.5% |
Notes: “–”, not available;
*
all cases were squamous cell carcinoma.
Abbreviations: DCR, disease control rate; OS, overall survival; PFS, progression-free survival.